Adlai Nortye Group Ltd.

Najnowszy kwartał, jaki mamy dla spółki Adlai Nortye Group Ltd.

Z własnego raportu 6-K spółki.

Co powiedział zarząd

“We continue to execute well across our pipeline, with initial clinical data on track for both of our pan-RAS(ON) inhibitor-based assets in 2027,”

Cytowane dosłownie z komunikatu i pokazywane tylko wtedy, gdy raport przypisuje wypowiedź konkretnej osobie.

Czym zajmuje się Adlai Nortye Group Ltd.

Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas: 1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company’s proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site. 2) Next-generation PD-1/L1 pathway modulating immunotherapies: including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells. 4

Własny opis spółki, tak jak widnieje na końcu komunikatu.